AbbVie (ABBV) recently affirmed a quarterly dividend of $1.64 per share, adding stability for shareholders amid a 12% ...

Three Motley Fool contributors believe they've found healthcare stocks that you can buy and hold forever. Here's why they ...

Abbvie (($ABBV)) announced an update on their ongoing clinical study. Study Overview: The MAVRiC Study, officially titled ‘A ...

Health Canada's recent approval of ELAHERE® for a challenging form of cancer marks a step forward for AbbVie (ABBV) in ...

AbbVie (ABBV) stock in focus as the company posts new data from a mid-stage trial for its lymphoma drug epcoritamab developed ...

This same concept can apply to investing in dividend stocks, although I prefer the term "double up" instead of "double down." ...

The one newcomer on the list was UCB’s Bimzelx, which knocked Intra-Cellular Therapies' Caplyta out of the running as it took ...

An AbbVie Inc. employee can’t save his whistleblower retaliation suit after a federal appeals court ruled Wednesday that he ...

Because Lewis only complained of regulatory, rather than fraudulent, violations in his internal communications with AbbVie, the company had no reason to think Lewis’s concerns revolved around the ...

We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. AbbVie Inc. is one of them.

AbbVie (ABBV) has outperformed the market over the past 5 years by 4.54% on an annualized basis producing an average annual return of 18.62%. Currently, AbbVie has a market capitalization of $375.08 ...